Loading…
Hosted by Practice Point Communications · 🇺🇸 US · EN · 51 episodes
Established thought leaders with verified media credentials.
Tune in to our hematology podcasts, where experts in the field of blood diseases unravel the complexities of hematology. Each episode covers the latest breakthroughs in the diagnosis, treatment, and management of hematologic conditions like leukemia, hemophilia, multiple myeloma and more. With in-depth discussions from leading hematologists, and insights from real-world cases, this podcast series provides healthcare professionals with the knowledge needed to navigate the world of blood disorders. Stay informed about cutting-edge research and hear inspiring stories of innovation in hematologic care.
Practice Point Communications hosts Practice Point®: Hematology, a education show with 51 episodes published.
Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and
Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and
Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and
Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and
Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and
CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additio
A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns
Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care. Through
In this podcast, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr.
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr.
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr.
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr.
Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring dis
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agent
In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for
In Highlights and Hindsight in CLL, Dr. Matthew Davids will describe the most significant ongoing studies and publications in CLL from 2024 and will detail their impact on the treatment continuum. This activity will enab
This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Die
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the
This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussio
Joseph Mikhael, MD
professor in the Applied Cancer Research and Drug Discovery Division · Applied Cancer Research and Drug Discovery, Translational Genomics
4 appearances on this show
Ajai Chari
University of California, San Francisco
5 appearances on this show
Sagar Lonial
Winship Cancer Institute | Emory University
5 appearances on this show
Cindy Neunert
Columbia University Irving Medical Center
1 appearance on this show
Joseph Mikhael
Applied Cancer Research and Drug Discovery, Translational Genomics
1 appearance on this show
Matthew Davids
Dana-Farber Cancer Institute
1 appearance on this show
Naval Daver
MD Anderson Cancer Center
1 appearance on this show
Guy Young
University of Southern California Keck School of Medicine
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Practice Point®: Hematology has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their education audience.
Practice Point®: Hematology is hosted by Practice Point Communications. The show is categorised under education and has published 51 episodes.
Practice Point®: Hematology has published 51 episodes.
Practice Point®: Hematology regularly covers education. It sits in the education category.
Practice Point®: Hematology is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Practice Point®: Hematology hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Practice Point®: Hematology average 23 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Practice Point®: Hematology's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.